Autoimmunity play a part in development of Chronic Obstructive Pulmonary Disease

Autoimmunity is the system of immune responses of an organism against its own healthy cells and tissues whereas Chronic Obstructive Pulmonary Disease (COPD) is a kind of lung disease characterized by long-term breathing problems and causes airflow blockage.

COPD, which includes chronic bronchitisand emphysema. Genome-wide association studies have identified several genes that contribute to the COPD development, however scientists still lack an understanding of the pathogenesis of theCOPD. The researchers examined the link between genetic variants in COPD and clinical phenotypes, or physical characteristics such as the historyof the disease, to understand the biological mechanisms concealing COPD.

Using genetic data from patients, the researchers performed a phenome-wide association study (PheWAS) of 16 reported COPD-associated Single Nucleotide Polymorphisms (SNPs) that were recognized by a genome-wide association study. SNPs represent a difference in a single DNA building block called a nucleotide are the common type of genetic variation among people.People are genetically very similar, but the main difference is because of theSingle Nucleotide Polymorphism (SNP).

                                        

Right now here's no treatment for COPD, Researchers are attempting to figure out to diagnose and to prevent it.So, some people with a specific SNP are more susceptible to get this disease.

SNP is also combinedwith several autoimmune diseases, likerheumatoid arthritis, type 1 diabetes thatsuggests a genetic link between COPDand autoimmune disease.

This study could provide awareness on opportunities for drug repurposing. The findings recommend future studies should explore the role of the immune system in the COPDpathogenesis. The researchers hope that scientists will investigate how normal SNPs, such as those associated with metabolic pathways or different nutrient receptors, are related to COPD.

Story Source:https://goo.gl/ioMzG3

By William Rose

Haloperidol as an Adjunctive Therapy is best to Placebo for Symptoms of Gastroparesis.

Gastroparesis is chronic, delayed gastric emptying during which food residues stayswithin the stomach longer than typical; symptoms incorporates nausea and vomiting. Gastroparesis can happen as a result of motor dysfunction, nerve damage or paralysis of the stomach muscles, and is related with other systemic diseases (diabetes mellitus) and surgical complications (gastrectomy). Haloperidol is afirst effective agent in combination using standard analgesic and also antiemetic agents for the gastroparesis treatment.

                                         

It is the first randomizedstudy, double- blind trial to estimate the effectiveness of haloperidol as an adjunctive therapy for the symptoms of gastroparesis and found that compared with gastroparesis patients randomized to placebo, those who received Haloperidol had a statistically significant decrease of nausea and pain, withoutany side effects, implying that the addition of haloperidol to conventional therapy was better than conventional therapy alone.

The study proposes that future research, with larger sample sizes, is needed to evaluate the external validity of the findings.

Haloperidol as an adjunctive therapy is best to placebo for symptoms of gastroparesis.

Story Source:

https://goo.gl/xAMf6U

By William Rose/August 01, 2018